Insider Monkey
Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations
📈
AI Sentiment
Highly Positive
9/10
- Home
- RPRX
RPRX
Royalty Pharma plc
as of 03-10-2026 3:53pm EST
$46.03
+$0.18
+0.40%
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 19.4B | IPO Year: | 2020 |
| Target Price: | $47.75 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 1.78 | EPS Growth: | -6.81 |
| 52 Week Low/High: | $29.66 - $47.86 | Next Earning Date: | 05-06-2026 |
| Revenue: | $2,378,193,000 | Revenue Growth: | 5.06% |
| Revenue Growth (this year): | 38.3% | Revenue Growth (next year): | 4.80% |
| P/E Ratio: | 25.56 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
Coyne Terrance P.
Sell
EVP & CFO
RPRX Mar 2, 2026
Avg Cost/Share
$46.84
Shares
34,791
Total Value
$1,627,533.79
Owned After
98,748
Coyne Terrance P.
Sell
EVP & CFO
RPRX Feb 23, 2026
Avg Cost/Share
$45.32
Shares
34,791
Total Value
$1,576,606.35
Owned After
98,748
Coyne Terrance P.
Sell
EVP & CFO
RPRX Feb 4, 2026
Avg Cost/Share
$43.29
Shares
20,163
Total Value
$872,912.73
Owned After
98,748
Coyne Terrance P.
Sell
EVP & CFO
RPRX Feb 3, 2026
Avg Cost/Share
$42.84
Shares
114,954
Total Value
$4,924,996.59
Owned After
98,748
Coyne Terrance P.
Sell
EVP & CFO
RPRX Feb 2, 2026
Avg Cost/Share
$42.08
Shares
108,424
Total Value
$4,562,904.77
Owned After
98,748
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 30, 2026
Avg Cost/Share
$41.09
Shares
20,000
Total Value
$821,810.00
Owned After
0
SEC Form 4
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 23, 2026
Avg Cost/Share
$40.26
Shares
20,000
Total Value
$805,110.00
Owned After
0
SEC Form 4
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 16, 2026
Avg Cost/Share
$39.52
Shares
20,000
Total Value
$790,346.00
Owned After
0
SEC Form 4
Urist Marshall
Sell
EVP, Research & Investments
RPRX Jan 9, 2026
Avg Cost/Share
$40.78
Shares
20,000
Total Value
$815,634.00
Owned After
0
SEC Form 4
Coyne Terrance P.
Sell
EVP & CFO
RPRX Jan 2, 2026
Avg Cost/Share
$38.42
Shares
69,582
Total Value
$2,673,041.24
Owned After
98,748
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | RPRX | EVP & CFO | Mar 2, 2026 | Sell | $46.84 | 34,791 | $1,627,533.79 | 98,748 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Feb 23, 2026 | Sell | $45.32 | 34,791 | $1,576,606.35 | 98,748 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Feb 4, 2026 | Sell | $43.29 | 20,163 | $872,912.73 | 98,748 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Feb 3, 2026 | Sell | $42.84 | 114,954 | $4,924,996.59 | 98,748 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Feb 2, 2026 | Sell | $42.08 | 108,424 | $4,562,904.77 | 98,748 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 30, 2026 | Sell | $41.09 | 20,000 | $821,810.00 | 0 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 23, 2026 | Sell | $40.26 | 20,000 | $805,110.00 | 0 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 16, 2026 | Sell | $39.52 | 20,000 | $790,346.00 | 0 | |
| Urist Marshall | RPRX | EVP, Research & Investments | Jan 9, 2026 | Sell | $40.78 | 20,000 | $815,634.00 | 0 | |
| Coyne Terrance P. | RPRX | EVP & CFO | Jan 2, 2026 | Sell | $38.42 | 69,582 | $2,673,041.24 | 98,748 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 11, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 11, 2026 · 100% conf.
AI Prediction SELL
1D
+0.25%
$44.36
5D
-1.74%
$43.48
20D
-1.87%
$43.42
Price: $44.25 Prob +5D: 0% AUC: 1.000
0001802768-26-000002
rprx-20260211FALSE000180276800018027682026-02-112026-02-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2026
Royalty Pharma plc (Exact Name of Registrant as Specified in its Charter)
England and Wales001-3932998-1535773 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Identification No.)
110 East 59th Street
New York, New York 10022 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (212) 883-0200 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered Class A Ordinary Shares, par value $0.0001 per shareRPRXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 11, 2026, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press release issued by Royalty Pharma plc, dated February 11, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ROYALTY PHARMA PLC
Date: February 11, 2026 By:/s/ Terrance Coyne Terrance Coyne Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001802768-25-000113
rprx-20251105FALSE000180276800018027682025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025
Royalty Pharma plc (Exact Name of Registrant as Specified in its Charter)
England and Wales001-3932998-1535773 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Identification No.)
110 East 59th Street
New York, New York 10022 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (212) 883-0200 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Class A Ordinary Shares, par value $0.0001 per shareRPRXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 5, 2025, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press release issued by Royalty Pharma plc, dated November 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ROYALTY PHARMA PLC
Date: November 5, 2025 By:/s/ Terrance Coyne Terrance Coyne Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001193125-25-173988
8-K
NY false 0001802768 0001802768 2025-08-06 2025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
Royalty Pharma plc (Exact Name of Registrant as Specified in its Charter)
England and Wales
001-39329
98-1535773
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S.
Identification No.)
110 East 59th Street
New York , New York
10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (212) 883-0200 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share
RPRX
The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 6, 2025, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
99.1
Press release issued by Royalty Pharma plc, dated August 6, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROYALTY PHARMA PLC
Date: August 6, 2025
By:
/s/ Terrance Coyne
Terrance Coyne
Chief Financial Officer
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Compare RPRX vs Leading Stocks
See how RPRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.